BridgeBio Pharma Inc to Discuss Additional Data from the Phase 3 ATTRibute-CM Study Transcript
Good day and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's additional clinical outcomes data from the Phase 3 ATTRibute-CM study in patients with transthyretin amyloid cardiomyopathy. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to introduce your speaker today, Dr. Daniel Judge, Professor of Medicine and Cardiology at Medical University of South Carolina and Co-Chair of the ATTRibute-CM Steering Committee; Dr. Neil Kumar, Chief Executive Officer, BridgeBio Pharma; Dr. Jonathan Fox, Chief Medical Officer, BridgeBio Pharma, Cardio and Renal.
I would now like to hand it over to Dr. Kumar.
Thanks so much, operator, and thanks to everyone who's listening in. Happy Diwali. I'll make my introductory remarks brief as I'm excited to listen to and learn from Dr. Judge today. I'll start briefly where I always start, which is a hearty thank you to the patients,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |